A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Learn more:

• clinicaltrials.gov: #NCT03871153

Study Contact: studies@hoosiercancer.org; (317) 921-2050.